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Abstract
It is becoming increasingly evident that the gastrointestinal microbiota has a significant impact on the overall
health and production of the pig. This has led to intensified research on the composition of the gastrointestinal
microbiota, factors affecting it, and the impact of the microbiota on health, growth performance, and more
recently, behavior of the host. Swine production research has been heavily focused on assessing the effects of feed
additives and dietary modifications to alter or take advantage of select characteristics of gastrointestinal microbes to
improve health and feed conversion efficiency. Research on faecal microbiota transplantation (FMT) as a possible
tool to improve outcomes in pigs through manipulation of the gastrointestinal microbiome is very recent and
limited data is available. Results on FMT in humans demonstrating the transfer of phenotypic traits from donors to
recipients and the high efficacy of FMT to treat Clostridium difficile infections in humans, together with data from
pigs relating GI-tract microbiota composition with growth performance has likely played an important role in the
interest towards this strategy in pig production. However, several factors can influence the impact of FMT on the
recipient, and these need to be identified and optimized before this tool can be applied to pig production.
There are obvious inherent biosecurity and regulatory issues in this strategy, since the donor’s microbiome
can never be completely screened for all possible non-desirable microorganisms. However, considering the
success observed in humans, it seems worth investigating this strategy for certain applications in pig production. Further,
FMT research may lead to the identification of specific bacterial group(s) essential for a particular outcome, resulting in the
development of banks of clones which can be used as targeted therapeutics, rather than the broader approach applied
in FMT. This review examines the factors associated with the use of FMT, and its potential application to swine
production, and includes research on using the pig as model for human medical purposes.
Keywords: Clostridium difficile, Faecal-microbiota-transplantation, Feed conversion, Gastrointestinal tract, Health,
Microbiota, Pig model, Pigs
Introduction
It has long been recognized that the gastrointestinal
tract (GI-tract) microbiota of the pig (and mammals in
general) has a major impact on the health and develop-
ment of the host [1–4]. Approximately 1014 bacteria
inhabit the mammal GI-tract [5–7] and 7,685,872 non-
redundant genes have been identified in the pig faecal
microbiome [8]. This gives an idea of the complexity of
the gut ecosystem, and intuitively, the plethora of pos-
sible functions the gut microbiota can have, and the po-
tential influence on the host. In line with this, Isaacson
and Kim [9] stated that the genetic diversity of the
microbiota in the gastrointestinal tract is immense and
has the potential to provide numerous biological activ-
ities that the host lacks.
The microbiota profoundly impacts an array of physio-
logical, developmental, nutritional, and immunological
processes of the host; and helps protect the animal from
colonization or overgrowth of pathogens and other non-
desirable species [1, 6, 10–12]. Conversely, the commensal
bacteria may have a series of effects that can negatively im-
pact the host, i.e., compete with the host for nutrients, pro-
duce toxic compounds, alter intestinal morphology, and
induce immune response in the GI-tract, which can impair
feed conversion efficiency [11, 13, 14].
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Many studies have been conducted dealing with the
composition and function of the GI-tract microbiota, the
impact of various factors upon it, and the influence of
the microbiota on the host. Previously, the microbiota
was investigated using predominantly phenotypic methods
such as culturing techniques and reporting of metabolite
concentrations; and in more recent years, culture-inde-
pendent molecular techniques, including denaturing gradi-
ent gel electrophoresis, terminal restriction fragment length
polymorphism, quantitative polymerase chain reaction, 16S
rRNA gene amplicon sequencing, and metagenome analysis
have been used [1, 15–22]. Further, other techniques, in-
cluding proteomics, transcriptomics, and metabolomics,
have also been used to investigate the function and impact
of the GI-tract microbiota on the host [23–27]. In addition,
these high resolution techniques are being advanced and
combined to examine the genotypic and phenotypic com-
ponents of the microbiome, in the burgeoning field of inte-
grative omics [28]. All this demonstrates the great efforts
being undertaken to decipher the microbial ecosystem of
the gastrointestinal tract and its influence on the host.
Richards et al. [11] described very precisely the main ob-
jectives of much of the research conducted regarding the
gastrointestinal ecology in pigs: i) to determine the opti-
mal microbiota for animal health and performance under
commercial growth conditions; and ii) to develop dietary
and other interventions to establish this microbiota.
In the search for strategies to improve performance
and prevent disease, manipulation of the GI-tract micro-
biota through different types of feed/feed additives/feed-
ing alternatives have been investigated. These include
ingredient composition, organic acids, plant extracts, es-
sential oils, probiotics, prebiotics, feed processing, fer-
mented liquid feed, zinc oxide, copper sulphate, and
antimicrobial peptides [1, 16, 29–37]. Only recently has
faecal microbiota transplantation (FMT) been investi-
gated for the purpose of GI-tract microbiome manipula-
tion in pigs with the aim of improving phenotypes in
these animals.
Faecal microbiota transplantation in pigs, from pig-to-pig
or human-to-pig, when used as a model for humans is also
a research area of interest and potential [38–46].
Although FMT is an ancient practice, both in humans
and animals (see section "A brief history of FMT" for
details), FMT in pig production aimed at improving
phenotypes in pigs through the establishment of a
donor microbiota in a recipient, has only recently been
examined [47–52].
The reasons for the recent introduction of this strategy
in studies with pigs likely follow various outcomes from
human medical research. Studies showing how different
phenotypes (obese and lean) in humans could be repro-
duced in recipient mice by faecal transplantation [53–
56], and the use of FMT in humans to treat recurrent
Clostridium difficile infections (rCDIs) with great suc-
cess (ca. 90% resolution) [57–62] have opened the door
to the possibility of using FMT to treat diseases and alter
GI-tract microbiota in pigs.
Furthermore, pig studies reporting evidence that the
host gut microbiota is linked to body weight, body
weight gain, and feed efficiency [63–68] have promoted
the hypothesis that manipulation of the GI-tract micro-
biota composition/function profile could lead to im-
proved growth traits in pigs.
Definition
Faecal microbiota transplantation is commonly defined
as a strategy to treat disease. The definition proposed by
various authors could be summarized as follows: FMT
refers to the transplantation of faecal suspension from
healthy donors to the GI-tract of a recipient patient, in
order to treat a specific disease associated with alteration
of gut microbiota, to achieve the treatment of gastro-
intestinal diseases, to treat dysbiosis-associated disease,
to increase intestinal microbial diversity and reestablish
a normal microbiome [47, 61, 69–72].
Gupta et al. [73] gave a somewhat different definition,
which in principle, does not include a diseased patient:
FMT is the administration of a solution of faecal matter
from a donor into the intestinal tract of a recipient in
order to directly change the recipient’s gut microbial
composition and confer a health benefit.
A brief history of FMT
According to Zhang et al. [74], the first human faecal
transplantation dates from the fourth century in China,
where the ingestion of a human faecal suspension by
patients who had food poisoning or severe diarrhea was
described. This gave positive results and was considered
a medical miracle. Later, in the sixteenth century, a
series of prescriptions using fermented faecal solutions,
fresh faecal suspensions, dry feces, or infant feces for
effective treatment of abdominal diseases with clinical
signs of severe diarrhea, fever, pain, vomiting, and con-
stipation were described [74]. In modern times, the idea
of FMT was revived by the work of Eiseman et al. [75],
reporting the recovery of four patients with pseudo-
membranous enterocolitis, which at the time had a 75%
mortality rate, after administration of enemas com-
posed of faeces from healthy individuals. Micrococcus
pyogenes, the agent of the disease, was isolated in the
stools of the patients prior to FMT, but could not be
detected after treatment.
In the past two decades, FMT has been an emerging
field in human medicine. Faecal microbiota transplant-
ation has been established as an effective treatment for
rCDIs. The successful use of FMT in managing rCDIs
has resulted in the exploration of FMT as a potential
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treatment for a range of diseases and disorders. This in-
cludes inflammatory bowel disease, irritable bowel syn-
drome, insulin resistance, multiple sclerosis, idiopathic
thrombocytopenic purpura, obesity, metabolic disease,
and some neuropsychiatric disorders [58, 76–80]. With
the exception of the use of FMT for rCDIs and inflam-
matory bowel disease, the studies in other diseases and
disorders are small and not repeated in sufficient num-
bers to allow solid conclusions to be drawn.
In veterinary medicine, the first reports on transplant-
ation of viable enteric bacteria, denoted ‘transfaunation’,
are considered to be those by the Italian anatomist
Fabricius Aquapendente in the seventeenth century. He
observed that cud taken directly from a healthy rumin-
ant and placed in the mouth of an animal that had lost
its capacity to ruminate would result in restoration of
rumination and health [81]. DePeters and George [82]
described the earliest printed reference about transfauna-
tion in Sweden to be from 1776 (Hjortberg) that stated “It
is common practice, even in the country side, to take the
fodder out of the mouth of a sheep or a goat to give it to
an animal which does not ruminate”. Brag and Hansen
[83] also reported that the Swedish peasants used to ad-
minister living ruminal microorganisms from a healthy
cow or sheep to an animal suffering from ruminal indiges-
tion by giving the diseased animal a cud bolus obtained
from the healthy animal. DePeters and George [82], in
their review, concluded that rumen transfaunation is a
widely accepted, successful procedure to treat simple indi-
gestion in ruminants. Further, the procedure has also clin-
ical applications for post-operative treatment of cattle
with left sided abomasal displacements [82].
Mullen et al. [84] in their review stated that whilst
there are no peer-reviewed studies of FMT in horses,
equine practitioners have a history of providing nasogas-
tric administration of ‘faecal tea’ from healthy horses to
horses with diarrhoea with anecdotal reports of success.
Faecal microbiota transplantation has also been inves-
tigated in poultry. For example, Nurmi and Rantala [85],
in a challenge study, observed a reduced susceptibility to
S. infantis infection in chicks administered with digesta
from healthy adult cocks. More recently, other studies
have aimed to improve parameters such as feed effi-
ciency in chickens using the FMT technique [86].
Regarding pigs, FMT has only recently been investi-
gated as a strategy to improve phenotypes with regards
to health and feed efficiency [47–52, 87, 88] (Canibe et
al., unpublished). On the other hand, there is a longer
history in the use of FMT and pigs when transplanting
human faeces to pigs with the aim of obtaining human
microbiota-associated (HMA)-pigs to be used as a model
for humans [38–42, 89].
The previous illustrates that the practice of FMT is an-
cient, practiced long before the current understanding of
gut microbiome and its influence on the host, and has
recently gained interest in several areas including medi-
cine, nutrition, and immunology, both in humans and
animals. As Aroniadis and Brandt [58] pointed out,
FMT received public attention more recently after sev-
eral studies were published showing that stool is a bio-
logically active, complex mixture of living organisms
with great therapeutic potential for CDI and perhaps
other GI-tract and non-GI-tract disorders. Therefore,
FMT in pig production is investigated in the context
of developing effective alternative feeding strategies
and production practices to improve performance or
reduce the use of antibiotic and heavy metals in order
to alleviate problems like bacteria resistance and en-
vironmental concerns, without impairing animal wel-
fare and growth performance.
Faecal microbiota transplantation in humans
Faecal microbiota transplantation and Clostridium difficile
infection
Clostridium difficile infections are a leading cause of
diarrhoeal disease in health care and community set-
tings, associated with severe morbidity and mortality
world-wide [90]. Clinical manifestation of CDIs ranges
from mild to moderate diarrhoea to toxic megacolon,
colonic perforation, and death [90]. Globally, since the
early 2000s, there has been an increase in incidence,
severity, and mortality of CDIs. This is largely attrib-
uted to the emergence of previously rare, epidemic
fluoroquinolone-resistant strains associated with in-
creased virulence [90, 91]. The key factor influencing
the occurrence of CDIs is exposure to antimicrobials
followed by the disruption of normal colonic micro-
biota. This results in the depletion of normal colonic
microbiota, which facilitates the proliferation of en-
dogenous or environmental C. difficile to proliferate
in the colon and produce toxins [91].
Since the hallmark of CDIs is the alteration of colonic
microbiota, restoration of this microbiota via FMT has
been utilized for the treatment of recurrent or relapsing
CDIs [92–94] and moderate CDIs that fail to respond to
standard antimicrobial therapy [57]. The rationale be-
hind the approach is to re-establish the dynamics and di-
versity of the microbiota, resulting in a return to normal
function of the colonic microbiota.
Faecal microbiota transplantation has been offered in
select centers across the world for decades, primarily as
a last effort to treat rCDI, which is characterized by
rapid infection recurrence upon antibiotic discontinu-
ation. Faecal microbiota transplantation has shown to be
highly effective in rCDI infection with about 85–90% of
patients being cured after FMT treatment [57, 58, 60–
62, 73]. The effectiveness of FMT on refractory CDI
(when patients do not respond to the antibiotic
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treatment) is less solidly established than on rCDI. Al-
though a few studies have reported high resolution rates
[95–97], in general, lower efficacy has been observed
[60, 61, 92]. Also, there is insufficient evidence to rec-
ommend FMT as a treatment for the first episode of
CDI [61]. Consequently, the Food and Drug Administra-
tion in the USA has approved the use of FMT as an inves-
tigational drug for the treatment of rCDIs after failure of
standard antimicrobial use [94] and the European Society
for Microbiology and Infectious Disease recommends
FMTas a treatment for rCDI [61, 98].
Administration method/route
A number of administration routes have been explored
for the FMT treatment of CDIs. Administration of fresh
or frozen homogenized faecal suspensions using naso-
gastric/nasoduodenal/nasojejunal tubes, gastroscopy,
rectal tube/enema, and colonoscopy has been utilized. A
review by Postigo and Kim [99] compared colonoscopy
and nasogastric tube for the administration of FMT.
Nasogastric tube insertion does not require endoscopy
guidance or bowel preparation, with the advantage of
greater accessibility and ease of use. On the other hand,
colonoscopy may have better therapeutic potential than
any other modalities by having the capacity to deliver
fecal infusion directly to the colon. Both routes appeared
to be highly effective. In a small study involving 20 pa-
tients, oral frozen encapsulated inoculum from unrelated
donors has also been used for the treatment of rCDI
with significant success rates (90% resolution of diar-
rhea) [100]. According to Cammarota et al. [61], many
systematic reviews and meta-analyses have reported that
colonoscopy achieves higher resolution rates of rCDI
and similar safety profile than other routes of delivery.
Donor characteristics
Choice of donors for the FMT treatment can vary, ran-
ging from family members, intimate partners, house
mates, and volunteer donors [101]. Although there have
been no adverse safety issues with FMT treatment,
donor screening is essential to minimize the risk of
transmission of communicable diseases. In addition, a
comprehensive risk assessment of the donor is required
to estimate the risk of a recent contraction of infectious
disease and rule out potential exposure to other infec-
tious agents that are not identified by currently available
laboratory methods [101].
Recipient preparation
One of the key considerations for recipient preparation
is the cessation of antimicrobial treatment 1–3 days
prior to FMT. When rectal tube/enema or colonoscopy
is used, bowel lavage prior to FMT administration on
the recipient is common to flush residual faeces,
antimicrobial residues, and C. difficile bacteria, spores
and toxins; and/or anti-diarrhoeals to prolong retention
of the faecal suspension in the colon [57, 61, 101, 102].
When the upper route is used, proton pump inhibitors
are administered, although their beneficial effect has not
been proven [61].
Faecal microbiota transplantation in mouse models
Faecal microbiota transplantation studies in mice have
shown promising results in a number of areas including
obesity, reversion of the dysbiotic effects of antimicrobial
use and chemotherapy, improved disease resistance, and
enhancing immune function. Evidence from mechanistic
studies suggest that obesity and associated metabolic
disorders are linked to composition and function of the
gut microbiota of the host [103]. Using mouse models, a
number of studies have investigated the role of gut
microbiota and FMT in controlling body weight and
obesity. Studies in mice have shown that diet shapes the
gut microbiota [104] and microbiota from obese individ-
uals have enhanced ability to harvest energy from diet
and energy stores [53, 105]. Using germ free mice, re-
searchers have demonstrated that obese traits attributed
to the microbiota are transmissible via FMT [55, 106].
Turnbaugh et al. [53] illustrated that germ free mice re-
ceiving microbiota from obese mice developed increased
body fat compared to those receiving microbiota from
lean mice. Another mouse experimental trial demon-
strated that FMT may assist in preventing or reversing
acute intestinal inflammation and mucosal barrier func-
tion following the administration of antimicrobials and
chemotherapy [107].
A study by Rosshart et al. [108] also showed that gut
microbiota of wild mouse can be viably preserved and
successfully transferred to laboratory mice, and the
newly transferred microbiota can be maintainable over
several subsequent generations of the recipient mice.
The study also showed that gut microbiota of wild mice
promoted host fitness and improved resistance to infec-
tious diseases such as influenza A and mutagen- and
inflammation-induced colorectal tumorigenesis [108].
In recent years, efforts have also been made to use mouse
models that resemble human microbiota to study various
human diseases and host-microbe interaction. A number of
experimental studies have successfully engrafted core hu-
man microbiota in both germ free and mice treated with
antimicrobials (HMA-mice) [55, 56, 109]. A comprehensive
study by Riduara et al. [56] demonstrated that FMT from
adult female human twin pairs discordant for obesity into
germ-free mice resulted in successful and reproducible
transmission of donor body composition phenotype [56]. A
similar phenomenon was also observed in germ free mice
by inoculating cultured anaerobic bacterial collection from
human twin pairs. In addition, this study was also
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successful in transplantation of human microbiota in germ
free mice with the preservation of the taxonomic and func-
tional features of the donor microbiota. It should be noted
that not all aspects of human microbiota and associated
functions are preserved in these mouse models.
Faecal microbiota transplantation in pig production
The aforementioned work in humans and mice are en-
couraging with regards to the use of FMT to promote
outcomes like feed efficiency, disease prevention and
treatment. However, the translation of this research into
practical applications for pigs require well designed and
executed, randomized control trials.
There are few studies in which FMT in pigs has been
investigated with the focus on pig production, rather
than as a model for human research, and they have all
been recently published [47–52, 72, 87, 88]. Besides
these, some other studies, although not using the pig as
a model for humans, have used FMT in trials with
gnotobiotic or cesarian-section delivered pigs investigat-
ing the impact of being colonized by a simple versus a
complex microbiota (FMT) e.g., [2, 110, 111]. These
studies show an impact of colonization on microbiota
composition and gut maturation in the recipients. How-
ever, this aspect of investigating the role of the gut
microbiota by comparing conventional animals with
those without a GI-tract microbiota or a simple one on
various parameters of the pig physiology and metabolism
is beyond the purpose of this review.
Some studies have examined various parameters
related to intestinal health, including intestinal devel-
opment, the epithelial barrier, and microbiota com-
position [47–51, 88]. Others have investigated the
use of FMT as a possible strategy to improve feed
efficiency of recipient pigs [52], Canibe et al. (un-
published); and others have tested the potential of
FMT to prevent or reduce disease [48, 72].
Description of studies
The experimental design of recently published studies
(Table 1) differ significantly depending on the hypothesis
being investigated, and to this end it is difficult to draw
a clear conclusion on the combined results. Below we
discuss the findings of the studies separately, and how
these relate to improved gut function in the pig.
Hu et al. [47] conducted a study in which faeces from
Jinhua pigs, more resistant to challenge by enterotoxi-
genic Escherichia (E.) coli K88 [112], were transplanted
to DLY (Duroc × Landrace × Yorkshire) newborn pig-
lets. The authors hypothesized that FMT would modu-
late the gut microbiota composition, and improve
intestinal barrier and immune function in the piglets.
They observed a higher average daily body weight gain
and lower diarrhea incidence in the piglets receiving
FMT compared to the control group during the first four
weeks after birth. Faecal microbiota transplantation had
no impact on the richness or α-diversity of the microbial
community. The relative abundance of Firmicutes in the
colon of recipient piglets was higher, and that of Proteo-
bacteria lower compared to the Control group. At the
genus level, Prevotella, Oscillospira, CF231, and Rumino-
coccus were more abundant, whereas Bacteroides, j2–29,
Sutterella, and Escherichia were less abundant in the re-
cipient piglets at one or both sampling times.
The impact of FMT on various parameters related to
epithelial barrier functions included up-regulation of
mRNA and protein expressions of the gel-forming
mucin 2 (MUC2), and relative expression of the tight
junction proteins zonula occludens-1 (ZO-1) and occlu-
din (OCLN) in ileum and colon in recipient piglets. In
addition, the number of goblet cells was higher in the
ileum and colon of the FMT piglets, which could explain
the higher expression of MUC2. These results taken to-
gether were considered as indicators of a beneficial effect
of the FMT on the development of the intestinal mucous
barrier in recipient piglets. In accordance, scanning elec-
tron microscope images of the villi in jejunum of recipi-
ent piglets indicated improved morphology as compared
to the donors.
The relative protein expression of ß-defensin 2 in the
ileal mucosa was increased in the recipient piglets, as
well as the relative expression of Toll-like receptor 2 and
Toll-like receptor 4, and the optical density of secretory
IgA cells in the colon. Increased expression of ß-defen-
sin 2, an antimicrobial peptide with a higher expression
level in the intestine of Jinhua pigs than in Landrace pigs
[47], was interpreted as playing a key role in contribut-
ing to the improvement of the resistance of recipients to
disease. The results of this study indicated that FMT
changed the population structure of intestinal microbiota,
which contributed to the improvement of intestinal
morphology, the development of the intestinal mucosal
barrier, and innate immunity in recipient piglets.
The same authors, Cheng et al. [48], conducted an-
other study with a similar transplantation procedure to
that used in their previous work [47]. By performing
proteomic analysis of colonic mucosal samples, differen-
tially expressed proteins between the donors and recipi-
ents included proteins involved in multiple processes,
such as energy production, lipid and amino acid metab-
olism, autophagy, oxidative stress, and inflammatory re-
sponses. The focus of the study was the impact of FMT
on mucosal autophagy, which has been reported as es-
sential in host defense against invasive bacteria [113].
The levels of autophagy-related proteins in the forkhead
box O signaling pathway and the antioxidant protein
superoxide dismutase 2 were increased, whereas the
levels of proteins related to inflammation response, were
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Table 1 Experimental design of studies on faecal microbiota transplantation in pig production








1 Effect on gut bacterial
community structure,
gut barrier and growth
performance
Control (saline) 6 litters;
9–10 pigs/
litter
1 27 1.5 mL daily, from d 1










1.5 mL daily from d 1 to
d 11. Orally












6 1.5 mL daily from d 1 to
d 11. Orally
3 Changes in the gut
microbiota induced by





Control (PBS) 6 1 14 1.5 mL every second day,








(+ NaCl at slaughter)
6 1.5 mL every second day,
from d 1 to d 14. Orally
Control (PBS)
(+ LPS at slaughter)
6 1.5 mL every second day,




1.5 mL every second day,
from d 1 to d 14. Orally
Faeces from Jinhua
adult pigs
(+ LPS at slaughter)
6 1.5 mL every second day,
from d 1 to d 14. Orally
4 Effects of early fecal
microbiota transplantation
on gut development in
sucking piglets
Control (saline) 6 3 56 10mL daily from d 1
to d 3; 10 mL every
second day from d 4 to
d 15; 20 mL every 5 days
from d 16 to d 46.
Intragastrically









(12 weeks of age)
6 10mL daily from d 1 to d 3;
10mL every second day
from d 4 to d 15; 20mL




(12 weeks of age)
6 10mL daily from d 1 to d 3;
10mL every second day
from d 4 to d 15; 20mL every




(12 weeks of age)
6 10mL daily from d 1 to d 3;
10mL every second day from
d 4 to d 15; 20mL every
5 days from d 16 to d 46.
Intragastrically
5 To identify and validate
gut microbes associated
with diarrhoea resistance
Control (none) 3 1 post-
weaning
11 None FMT reduced diarrhoea
in recipients; FMT
caused shifts in the
microbiota of recipients
towards that of donors
Control (saline) 3 2 mL every second day




3 2 mL every second day




3 2 mL every second day
from d 10 to d 18. Orally
Oxytetracycline 3 2 mL at weaning.
Intramuscular
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Table 1 Experimental design of studies on faecal microbiota transplantation in pig production (Continued)















Control (saline) 5 1 21 3 mL every day from d 1





piglets on day 7, while
less effect on day 21
Amoxicillin 3 3 mL every day from d 1
to d 6. Orally
Faeces from
the dam
5 3mL every day from d 1
to d 6. Orally
7 Whether FMT in sows
and/or neonatal offspring




Control (saline) 18/12 d 70 of
gestation




Faeces from 4 finisher
pigs with the lowest RFI
to piglets at birth
18/12 8 mL at birth. Orally
Faeces from 4 finisher
pigs with the lowest RFI
to piglets at birth, 3, 7,
and 28 d of age
18/12 8 mL at birth, 3, 7, and
28 days of age. Orally
Faeces from 4 finisher pigs
with the lowest RFI to sows
18/12 200mL d 70 and d 100
of gestation. Intragastrically
Faeces from 4 finisher pigs
with the lowest RFI to sows,
and piglets at birth
18/12 200mL d 70 and d 100 of
gestation. Intragastrically.
8 mL at birth to piglets.
Orally
Faeces from 4 finisher pigs
with the lowest RFI to sows,
and piglets at birth, 3, 7,
and 28 days of age
18/12 200mL d 70 and d 100 of
gestation. Intragastrically.
8 mL at birth, 3, 7, and
28 days of age. Orally
8 Microbiota from donors
differing in composition
can be established in
recipient pigs
Colon digesta from growers
(18weeks old) fed a
Control diet







fed a Control diet added
170 ppm copper




fed a Control diet added
40 ppm tylosin




fed a Control diet added
1% benzoic acid
20 20mL on d 4 and d 18
post-weaning. Orally
9 To assess the alleviation








Challenged E.coli K88 +
PBS
6 100mL K88 from d 15 to
d 17+ 100mL PBS on
d 18 to d 20
Challenged E. coli
K88 + faeces
6 100mL K88 from d 15 to
d 17+ 100mL faeces on
d 18 to d 20
10 FMT prior to co-infection








25 51 5 mL every day from












5 mL every day from
d 1 to d 7 post-weaning
a1: Hu et al. [47]; 2: Cheng et al. [48]; 3:Geng et al. [50]; 4: Diao et al. [49]; 5: Hu et al. [51]; 6: Lin et al. [88]; 7: McCormack et al. [52]; 8: Canibe et al. (unpublished);
9: Cheng et al. [48]; 10: Niederwerder et al. [72]
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decreased in the recipient. Therefore, the results sug-
gested that FMT triggered mucosal protective autophagy
and thereby protected the integrity of the intestinal
barrier.
In another study, Geng et al. [50] investigated FMT as
a strategy to maintain intestinal homeostasis by regulat-
ing mucosal integrity and immune responses in piglets.
Performing FMT to lipopolysaccharide (LPS)-treated
piglets significantly alleviated the decrease in colonic
crypt depth/tissue thickness ratio induced by LPS chal-
lenge; increased the height and quantity of microvilli as
well as the distribution of epithelial cell junctions in
colon; prevented the LPS-induced reduction in epithelial
Ki67-positive cells (a measure of cell proliferation); in-
creased the relative mRNA expression of adherens junc-
tion protein E-cadherin (provides cell-cell adhesion in
relation to epithelial barrier); and increased the relative
mRNA expression of the anti-inflammatory cytokine
transforming growth factor-β1, while reduced that of the
pro-inflammatory cytokines interleukin (IL)-1β, IL-6,
tumour necrosis factor-α, and interferon-γ, and that of
chemokine monocyte chemotactic protein 1. These re-
sults suggested that FMT can help to alleviate the dis-
ruption of the epithelial barrier and the inflammatory
responses caused by LPS challenge.
Regarding microbiota composition in colon digesta, no
effect of FMT on diversity at operational taxonomic unit
(OTU) level was detected. Alpha-diversity indices were
significantly higher at the class and order level in the
FMT group as compared to the control group; and sig-
nificant differences in the composition of gut microbiota
between the two groups was detected at phylum, family,
and genus level, arguably indicating an overall healthier
microbiome profile. The metabolome profile of colon
digesta of the control group and the FMT group clus-
tered separately. Further, metabolite set enrichment ana-
lysis showed that tryptophan metabolism was the most
significantly affected metabolic pathway in the recipient
colon, which was interpreted as playing a role in main-
tenance of the intestinal barrier following FMT.
The impact of transplanting faeces with varying bac-
terial composition was investigated by Diao et al. [49] by
using donor pigs of three different breeds (Tibetan,
Yorkshire, and Rongchang) to suckling (DLY) piglets.
Piglets receiving faeces from Yorkshire and Rongchang
pigs had a higher post-weaning diarrhea index than con-
trol piglets receiving saline and those receiving faeces
from Tibetan pigs. In comparison to the control, the
group transplanted with Yorkshire faeces showed various
negative responses related to epithelial barrier, i.e., lower
mRNA expression of the tight junction protein ZO-1 in
ileum, lower goblet cell numbers in ileum and colon,
and lower mucin 1 (MUC1) expression in colon; intes-
tinal development, i.e., lower expression of glucagon-like
peptide-2 (GLP-2), angiogenin 4 (ANG-4), and insulin
like growth factor-1 receptor (IGF-1R) in ileum; digestion
and absorption, i.e., lower lactase and γ-glutamyltransferase
(γ-GT) activity in the jejunum, lower expression of zinc
transporters-1 (ZNT-1) in duodenum and jejunum, of diva-
lent metal transporter-1 (DMT1) in jejunum, and of solute
carrier family 7 (SLC7A1) in ileum; and gut health, i.e., high
serum concentration of LPS, and lower superoxide dismut-
ase activity (SOD) in jejunum. Similarly, the piglets receiv-
ing faeces from the Rongchang pigs showed various
negative responses compared to the control group: lower
villous height in ileum; lower expression of GLP-2 in ileum,
ANG-4, and IGF-1 in colon; lower lactase and γ-GT activity
in jejunum; lower total tract digestibility of dry matter,
crude protein, energy, crude ash, ether extract, and calcium;
lower expression of regeneration protein IIIγ in colon;
lower expression of ZNT-1 in duodenum, and DMT1 in je-
junum; and lower SOD activity in jejunum.
On the other hand, the impact of transplantation of
faeces from Tibetan pigs was smaller, and considered
more beneficial: higher level of the digestive and absorp-
tive enzyme activities Na+, K+-ATPase, and Ca+,
Mg+-ATPase enzymes in jejunum; higher expression of
SLC7A1 in duodenum; higher expression of the
anti-inflammatory cytokine IL-10 in colon; and higher
numbers of lactobacilli in cecum and colon compared to
control pigs.
The data indicated that the impact of transplanting
faeces from the different donor breeds [49] was different,
that is, faecal microbiota from Yorkshire and Rongchang
pigs to DLY suckling piglets had adverse effects on gut
development and function, whereas transplantation of
faecal microbiota derived from the Tibetan pigs had a
lower impact on the recipients, with some positive ef-
fects on intestinal health and function.
Hu et al. [51] conducted a series of studies to investi-
gate the mechanism behind the positive effects observed
by FMT and which gut microbes confer this efficacy.
This was done in the context of finding alternatives to
antibiotics to prevent diarrhea in early-weaned piglets.
Faecal microbiota from healthy Congjiang miniature pig-
lets, which were considered to have stronger resistance
to post-weaning diarrhoea than Landrace × Yorkshire
(LY) piglets, was administered to LY piglet recipients or-
ally prior to weaning. Transplantation at a low dose (and
not at a high dose) significantly decreased diarrhea in re-
cipient piglets.
Faecal transplantation affected both α- and ß-diversity
and the functional profile of the microbiota. Five bacter-
ial species (Lactobacillus frumenti, L. gasseri LA39,
Butyricicoccus pullicaecorum, Eubacterium hallii, and
Blautia hansenii) exhibited significantly higher relative
abundance in the FMT piglets than in the Control group
at all sampling times. A follow up study with piglets in
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which the five-bacteria consortium or each bacterium
separately were transferred orally showed that the con-
sortium and L. gasseri LA39 or L. frumenti alone signifi-
cantly decreased diarrhea. Further studies indicated that
the bacteriocin gassericin A, produced by L. gasseri
LA39 and L. frumenti, conferred diarrhea resistance by
increasing intestinal fluid absorption and decreasing in-
testinal fluid secretion.
Thereby, the data suggested that L. gasseri LA39 and
L. frumenti may be worth testing further as candidate
bacteria for preventing diarrhea in piglets. Another find-
ing in this study was that the anti-diarrhoea effects of
FMT were stronger using a low-dose faecal suspension
than upon using a high-dose faecal suspension, suggest-
ing that the impact of FMT may be dose dependent.
Lin et al. [88] used FMT to suckling piglets with ma-
ternal faeces as a strategy to positively affect the process
of gut microbiota colonization in piglets. Differences in
abundance of some bacterial members in stomach, ileum
and colon digesta, as well as of the metabolic profile in
colon digesta were observed between the Control and
FMT group. However, the impact of these changes on
the health of the recipients was not clear.
One of the studies investigating FMT as a strategy to
improve feed efficiency in recipients by using faeces
from highly feed-efficient donors is that of McCormack
et al. [52]. In their study, faeces from finisher pigs with
low residual feed intake (high feed efficiency) were used
and transplanted either to sows and or to their offspring,
i.e., the impact of FMT given to sows, or the offspring,
or to both was investigated.
A negative impact of FMT on performance was mea-
sured, since offspring from transplanted sows were
lighter than offspring from control sows, and trans-
planted offspring were also lighter than control off-
spring. Numerous differences in microbiota composition
were detected as a result of FMT at the phylum and
genus levels and at the various sampling time points and
sites. Some of the changes in microbiota composition
were discussed by the authors as possible contributors
to the impaired growth of the offspring due to FMT, in-
cluding a higher abundance of Bacteroidetes, which have
been linked with lower adiposity in pigs; increased abun-
dance of Bacteroides and of Prevotella, related to lower
adiposity in pigs and poorer feed efficiency, respectively;
and reduction in Faecalibacterium, known for its
anti-inflammatory properties and linked with heavier
body weight in pigs. Further, FMT practiced to sows or
to the piglets impacted predicted functions of the micro-
biota, which belonged to mainly carbohydrate and amino
acid and lipid metabolism and were mostly in the ileum.
The offspring from transplanted sows compared to
those from control sows showed various characteristics
related to epithelial barrier and possibly absorptive
capacity, probably caused by changes in microbiota com-
position, which were hypothesized by the authors to ex-
plain the negative impact of FMT on performance of the
recipients. These included lower number of duodenal
goblet cells but higher number of ileal goblet cells per
μm of villus height; reduced jejunal villus height-to-crypt
depth ratio, reduced ileal villus height, width, and area,
and lower ileal crypt depth; and upregulation of the
genes encoding the tight junction proteins ZO1 and
OCLN. Upregulation of the gene encoding the tight
junction protein OCLN was also detected in the off-
spring subjected to FMT. Interestingly, in contrast to
[47] and others, e.g. Ulluwishewa et al.[114] and Robin-
son et al. [115], who considered the tight junction pro-
tein expression levels to be associated with improved
intestinal barrier integrity, McCormack et al. [52] inter-
preted the upregulation of OCLN and ZO1 genes as a
factor contributing to impaired absorptive capacity, due
to a more selective duodenal paracellular permeability.
Further, McCormack et al. [52] also considered that the
greater number of goblet cells might have resulted in
overproduction of mucin in the ileum, forming a phys-
ical barrier that decreased nutrient absorption. These re-
sponses together with the reductions in ileal villus
height and area observed would lead to an impaired nu-
trient absorption in FMT piglets.
Furthermore, multiple inoculations in offspring ampli-
fied the negative impact in some instances. Also, the
combinative effect of maternal and offspring FMT
showed additive negative effects seen as a much lower
slaughter weight and a greater impact on ileal villus
height in pigs on the combined treatments than in
FMT-treated offspring from control sows.
In line with the objective of the study of [52], Canibe
et al. (unpublished) conducted a study to investigate
whether transplanting the colonic microbiota from pigs
fed diets known to result in high feed efficiency would
establish in recipient pigs. The aim being to achieve an
improved feed efficiency in the recipient pigs. The ex-
perimental diets fed to the donors were a control diet,
and control diet with the addition of 170 ppm copper as
copper sulphate, 40 ppm tylosin, or 1% benzoic acid.
The preliminary results from this study indicated that
FMT had only a small impact on the microbiota com-
position of the recipient pigs as measured 10 weeks after
the last transplantation. In order to get more in-depth
information on the potential impact of FMT on the host’s
metabolism, samples will be further explored by deep
metagenomics sequencing.
A few studies have investigated FMT as a strategy to
ameliorate the negative impact of bacterial or viral infec-
tions in pigs.
Cheng et al. [48] investigated whether FMT could re-
duce the negative impact of Escherichia coli K88
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infection on the gastrointestinal epithelium of piglets,
and positive results were reported. Faecal transplantation
alleviated the negative impact the E. coli K88 infection
had on weight gain and diarrhea incidence on the pig-
lets. Further, the damage caused by E. coli infection on
jejunal villi was alleviated by FMT; the number of goblet
cells and the protein levels of MUC2, ZO-1, and OCLN
in colonic mucosa of the infected piglets receiving FMT
was higher; and the serum diamine oxidase activity and
D-lactate (also used as indicators of intestinal barrier)
lower as compared to the infected piglets not receiving
FMT.
Niederwerder et al. [72] conducted a study to test the
potential of FMT to prevent porcine circovirus associ-
ated disease (PCVAD) in a challenge study with pigs
co-infected with porcine circovirus type 2 (PCV-2) and
porcine reproductive and respiratory syndrome virus
(PRRSV). According to Niederwerder et al. [72], in
co-infection studies, the presence of increased micro-
biome diversity is linked to a reduction in clinical signs,
an outcome that can be hypothesized to be manipulated
by providing FMT.
The FMT treated group had lower morbidity, lower
mortality, and fewer pigs showed weight loss due to
PCVAD. In general, virus replication during peak
clinical disease was reduced in the FMT group; and
the production of antibodies directed at both PRRSV
and PCV-2 was higher and at more sustained levels.
No impact of FMT on bacterial diversity or global
changes in bacterial composition was detected. Some
differences between the groups were found, though,
the FMT having a higher relative abundance of Veil-
lonellaceae, Lachnospiraceae, and Ruminococcaceae in
faeces. These changes were hypothesized to partly ex-
plain the beneficial impact of FMT by helping the
host hydrolyzing feed substrates. Modulation of the
systemic immune response by FMT was also specu-
lated to contribute to the results. However, the num-
ber of pigs used in this study was low, and it is
unclear if PCVAD or PRRSV-associated disease was
the underlying cause of clinical disease, due to the
sporadic, multifactorial nature of PCVAD.
Discussion of the results
The studies presented above and summarised in Table 1
display both positive and negative results [47–52, 72]
showing that the possibility to reprogram the porcine in-
testinal microbiota via FMT, with resultant alterations in
host phenotype exists, although the mechanisms and
optimum protocols are not clear.
Many factors can contribute to the varying outputs
and given the importance of this aspect, there have been
attempts to standardize procedures to prepare FMT
[116]. The study of Diao et al. [49] suggests that donor
is an important factor, since, with all other factors simi-
lar, the response of the recipients differed depending on
the donor microbiota. Further, the results of Hu et al.
[51] showing that the anti-diarrhoea effects of FMT were
stronger using a low-dose faecal suspension than upon
using a high-dose faecal suspension, and those of Mc-
Cormack et al. [52] showing that multiple FMT inocula-
tions in offspring amplified the negative impact in some
instances could suggest that higher doses of transplant
microbiota are not necessarily better, perhaps because
some remnant microbiota needs to be present in the re-
cipient or the level of ‘tolerance’ to bacteria from an-
other subject has a limit. Characteristics of the
recipients, ranging from health status to genetic back-
ground can also be assumed to affect the impact of
FMT. Due to the low number of studies conducted so
far, there are many aspects that have not been answered
yet: should the donors be of a similar age as the recipi-
ents?; should administration routes be oral or by
enema?; at what age should FMT be applied?; how much
material should be transplanted?; and what is the
optimum number of transplantations?.
As discussed above, the literature on FMT in humans is
extensive. However, while FMT in humans has mainly
been used so far to treat diseased patients, in the case of
most of the studies presented here dealing with pig pro-
duction, FMT was practiced in non-diseased animals in
an attempt to improve their health and/or feed efficiency.
As for most aspects of microbial ecology of the gut,
the function profile more than the microbiota profile is
relevant for the impact on the host. Accordingly, as dis-
cussed by Arrieta et al. [117], it is possible that the
changes in phenotype in the recipients are not caused by
the compositional characteristics of the engrafted micro-
biome, but by the ‘engrafted functions’, that is,
bacterial-derived metabolites or components known to
have strong metabolic and immunomodulatory effects.
This is in line with the data of studies on CDI in humans
by Weingarden et al. [118], Staley et al. [119], Smillie et
al. [120], and Staley et al. [121], suggesting that complete
engraftment is not necessary to resolve CDI, rather, that
bacteria with certain functions potentially provide
resistance to infection. Therefore, a combined
composition-function analysis of the transplanted micro-
biome will provide better insight into the relevant mech-
anisms involved in the phenotypic change in recipient
animals [117].
The level of engraftment necessary in pigs to improve
feed efficiency or health/reduce risk of disease is not
known. It could be hypothesized that, as for humans, es-
tablishment of a certain consortium of bacterial species/
strains with the specific functions needed to improve
these phenotypes in the recipients would be enough.
However, the reason for practicing FMT is precisely that
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this beneficial consortium has not been identified. An
example of a study trying to identify the specific bacteria
or group of bacteria conferring the beneficial effects of
FMT is that of Hu et al. [51] who, by performing various
follow-up studies, showed that two specific bacterial spe-
cies and via production of a specific bacteriocin could
explain the reducing effect of FMT on diarrhea develop-
ment in piglets.
Interestingly, not all the pig studies described report
the level of engraftment, but rather differences among
recipient groups. According to Arrieta et al. [117] this is
not only the case for pig studies, but also many studies
with HMA-mice do not report whether the transplanted
microbiota has been established or only report changes
at higher taxonomic levels.
While increased microbial diversity after FMT is con-
sidered an important contributor to the beneficial im-
pact of FMT to CDI patients [76, 122], it should be
remembered that these patients, besides having lower di-
versity due to CDI, contrary to piglets, have gone
through an intensive antibiotic treatment, which is
known to reduce microbial diversity [123], before FMT.
In order to achieve a successful establishment of
the transplanted microbiota it could be argued that
using donors of the same age as the recipients might
be more appropriate. This is based on the hypothesis
that animals of the same age have a more similar mi-
crobial ecosystem than those of different ages and
therefore, the microbiota would more easily establish.
On the other hand, using adult pigs as donors to
much younger recipients could be based on the fact
that during birth, piglets are colonised with the sow’s
microbiota, which is considered beneficial for the
general development of the offspring as compared to
piglets born by cesarean-section and, therefore, with-
out contact to the mother’s microbiota [124, 125].
The selection of the most appropriate donor, as men-
tioned above, needs to be further investigated.
The few studies published so far related to FMT in
pigs as a strategy to improve health and/or performance
do not allow a definitive conclusion on its effectiveness.
Much more data is required in which the various factors
that may affect the outcome are investigated.
Moreover, one area that, in our opinion, would also be
worth covering to a greater extent is the use of FMT to
treat certain pig diseases, for example, post-weaning
diarrhoea. The microbiota of pigs suffering from diar-
rhea is dysbiotic, and FMT could help establishing a
‘normal’ population (which partially resembles the situ-
ation of CDI in humans).
If the results of using FMT as a strategy to improve
feed efficiency or health in non-diseased pigs or to treat
diseased pigs shows promise, putting this strategy into
practice should be feasible. This would, for example,
require treating the animals individually. While this ini-
tially may seem unviable from an economic point of
view, it could be combined with routines in pig produc-
tion currently requiring such effort, for example, iron
supplementation and castration, or the individual treat-
ment of pigs in quarantine or hospital pens.
On the other hand, in Critical Views in Gastroenter-
ology and Hepatology [126], it was stated that ‘If we are
still doing faecal transplants in 5 years’ time, we have
failed. We will probably move into a situation in which a
patient would be given a specific cocktail of organisms
in a highly quality-controlled context’. There is no doubt
that identifying the specific group of bacteria that lead
to the searched outcome instead of using the whole fae-
cal sample, with the risks and variability that can bring
with it, would be preferable and should be searched for
[51, 56, 121, 127]. In fact, studies using FMT can help
acquiring this knowledge, just as it is the case in human
research [118–121].
Faecal microbiota transplantation in research
Faecal microbiota transplantation is also practiced when
the pig is used as a model for humans, either by trans-
planting faeces from pigs to pigs [45, 46], or transplant-
ing microbiota from humans to pigs to obtain
HMA-pigs with the aim of investigating aspects relevant
for humans [38–44, 89, 128, 129].
Description of studies
In order to test the hypothesis that the transplantation
of gut microbiota could transfer certain immunological
characteristics from donors to recipients, Xiao et al. [45]
transplanted faecal microbiota of two pig lines, York-
shire and Tibetan (Yorkshire being more susceptible to
disease and Tibetan being more resistant), to commer-
cial hybrid newborn piglets, followed by induction of
acute colitis using dextran sulphate sodium (DSS).
Differences in microbiota composition and several im-
munological parameters, including lower levels of
pro-inflammatory cytokines in Tibetan pigs, between the
two donor breeds were observed. Oral DSS administra-
tion induced observable acute colitis only in the pigs
colonized with the “Yorkshire microbiota”. Further, sev-
eral inflammatory markers and expression of various
molecules related to immune activation were promoted
by DSS administration only in pigs that received the
“Yorkshire microbiota”. Therefore, the transplantation
with microbiota from Tibetan microbiota seemed to con-
fer resistance to the inflammation induced by DSS, with
less severe colonic haemorrhage and milder histological
impact compared to FMT from Yorkshire donors. Lower
abundance of Bacteroidetes and Prevotella, and higher
abundance of Fibrobacter and Lactobacillus in the faeces
of Tibetan pigs compared to Yorkshire pigs was
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speculated to be involved in the higher resistance to dis-
ease by Tibetan pigs. This is however, not proven.
Brunse et al. [46] used preterm piglets as a model to
investigate the impact of FMT provided by different
routes, i.e., either orally and rectally, or only rectally, on
various parameters in relation to necrotizing enterocoli-
tis (NEC) in preterm infants. This was done in an at-
tempt to investigate the potential of FMT to prevent/
treat NEC. Colon content from healthy suckling piglets
was used as transplantation material. Five-day (the
length of this study) survival was significantly reduced in
the group administered oral + rectal FMT compared
with controls (no FMT). Faecal microbiota-transplanted
animals surviving until day 5 showed reduced growth
compared with the control, but 60% relative reduction in
NEC incidence. The results obtained in animals receiv-
ing FMT only via the rectum were more positive. In
contrast to the results from piglets receiving oral + rec-
tal FMT, 5-day survival was unaffected. Further, neither
of the clinical parameters, motor activity, and growth
rate were affected by rectal FMT; and importantly, FMT
reduced the relative NEC incidence by 75% when admin-
istered only rectally.
In conclusion, oral FMT increased the risk of lethal
sepsis, whereas rectal FMT protected against NEC with-
out causing adverse effects. This indicated that the route
of administration of FMT can be crucial for the output
obtained. The authors proposed the introduction of
lactate-utilizing bacteria such as Bacteroides as the mode
of action behind the positive impact of FMT on NEC.
This would change microbial metabolism towards lactate
consumption and short chain fatty acids (SCFA) produc-
tion. The combination of lower lactate and potential epi-
thelial exchange of SCFA and bicarbonate would ensure
a neutral luminal pH, which sustains a physical barrier
and thereby protects the epithelial surface from bacterial
invasion, and prevent mucosal damage and NEC.
As mentioned above, a different area of research of
FMT in pigs is that in which pigs are used as a model
for human research by obtaining HMA-pigs. That is,
faeces from humans are transplanted to pigs with the
purpose of obtaining pigs with human-like microbiota.
This then allows studies to explore aspects of relevance
for human gut ecology, nutrition, disease pathology, im-
munology, and drug discovery in pigs.
Conventional pigs, germ-free pigs, and germ-free pigs
colonized with single or multiple bacterial strains have
been used as model for humans since at least 1971 (e.g.,
[12, 130–136]. The pig- and human microbiome are
more similar than, for example, the mouse and human
microbiome [8], leading researchers to conclude that pig
models are more appropriate as a surrogate for the hu-
man microbiome. However, the pig and human micro-
biomes are sufficiently different [8, 38, 137, 138], which,
combined with the belief that the effects of single or
multiple bacteria on the host do not reflect completely
those of complex microbiota [110, 135, 137], has re-
sulted in the need for better models. The premise of the
HMA-pig model is that these animals respond to the ex-
perimental treatments in a similar way to humans, and
more similarly than the mentioned conventional or sin-
gle/multiple associated germ-free pigs. Further, the use
of the pig rather than rodents, which have widely been
used, including rodents with human-associated micro-
biota [117, 139–141], as a model for humans makes re-
search more expensive, requires larger facilities, and
often takes longer. The efforts made to establish a pig
model are based on the belief that it is a better model
than rodents due to the closer resemblance between pigs
and humans with respect to the anatomy, physiology,
immune system, metabolism, gut microbiome, and om-
nivorous diet [8, 136, 142–144].
Pang et al. [38] transplanted faeces from a boy to
germ-free piglets delivered by cesarean section. Accord-
ing to the authors, they succeeded in establishing a
donor-like microbial community, with minimal individ-
ual variation. Further, the microbial succession with
aging of the ex-germfree piglets was also reported to be
similar to that observed in humans. The latter was based
on results showing that introduction of solid food to the
piglets during the weaning period led to a reduction of
bifidobacteria, which is in line with the shifts observed
from breast-fed infants to adulthood in humans.
Clustering analysis based on the fingerprints of Entero-
bacterial repetitive intergenic consensus sequence-PCR
(ERIC-PCR) of intestinal microbiota of 10 unrelated
healthy human individuals, five conventional piglets
and two HMA-piglets showed that the human and
HMA-piglet samples clustered together and the con-
ventional piglet samples clustered in another group,
which indicated that the DNA fingerprints of HFA pig-
lets were more similar to that of humans than to the
CV piglets.
Zhang et al. [40] had the aim of developing animal
models enabling the manipulation of human microbiomes
and the study of the impact of such perturbations on the
host. They conducted three trials with a small number of
animals (from 2 to 4 piglets) delivered by cesarian section,
kept in sterile isolators, and fed with human infant milk
formula or a sterile grower diet. Faeces from human adults
or a breast-fed baby were transplanted to the piglets. The
results obtained were variable, and according to the au-
thors, microbiota composition of HMA-piglets trans-
planted with the infant donor tended to converge towards
that of the donor, while that of HMA-piglets harboring
the adult human microbiota did not. The few number of
animals included and short sampling period makes it diffi-
cult to draw conclusions from these studies, though.
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Zhang et al. [41] used the HMA-pig model to study
aspects of rotavirus infection in humans and its relation
to the gut microbiota. More specifically, the effect of a
probiotic on the composition of the transplanted micro-
biota following rotavirus vaccination and challenge. The
model was hypothesized to help testing interventions to
prevent or treat infantile diarrhea caused by rotavirus
and improve enteric health and immunity. Faeces from a
cesarian section-delivered infant were transplanted to
germ-free newborn piglets. Observing the bacterial com-
position of the human faeces and piglet colon digesta
obtained by 16S rRNA gene amplicon sequencing,
Zhang et al. [41] concluded that the recipient pigs car-
ried microbiota similar to the human donor’s micro-
biota. However, this conclusion was not based on
statistical analysis, what makes this conclusion
uncertain.
Wen et al. [42] used HMA-pigs with the aim of estab-
lishing a model to study aspects of rotavirus infection in
infants, too. Faeces from an infant were orally trans-
planted to germ-free piglets. They concluded that the
HMA germ-free pig model is an appropriate model for
studying immune responses to vaccines for human rota-
virus infection and for evaluation of the immunomodu-
latory effects of probiotics. No analysis of the microbiota
composition of the donor or recipient subjects was con-
ducted, so it is unknown whether the donor microbiota
established, or whether a similar output would have
been seen if the animals had been transplanted with pig
faeces. Furthermore, approximately 21% of the pigs be-
came ill within several days after the oral administration
of the microbiota from the infant donor, Klebsiella oxy-
toca being the likely cause of the illness. In line with
these results, Wei et al. [39] reported that 17 of 24 pig-
lets died due to the opportunistic pathogen Klebsiella
pneumoniae present in the transplanted animals, which
originated from an apparently healthy human donor of
11 years of age.
A series of studies, [44, 89, 128, 129] investigated vari-
ous aspects of protein malnutrition and rotavirus infec-
tion in HMA-pigs. Kumar et al. [89] used the HMA
model to test the hypothesis that malnutrition exacer-
bates rotavirus disease severity in infants. Faeces from
a baby were transplanted to caesarean-delivered
germ-free piglets. Seven days later, the microbiota of fae-
ces and GI-tract of the piglets was analyzed and com-
pared to the human microbiota transplanted gut.
Despite differences in the microbial population between
the donor and recipient both at phylum (e.g., Actinobac-
teria had a relative abundance of 40% in the donor and
only ca. 2% in the recipients) and at lower taxonomic
levels, the results were interpreted as showing a represen-
tative colonization of the pig intestines by the transplanted
microbiota. This was based on the observation that the
recipient pigs shared the majority of OTUs identified in
the donor faeces but at different proportions. One of the
differences between the transplanted microbiota and that
found in the pigs was related to bifidobacterium (which is
within the Actinobacteria phylum) being present in higher
abundance in the transplanted microbiota than in that of
the recipient piglets, which the authors attributed to the
effect of the diet. The donor infant was breast-fed, which
is known to promote bifidobacteria, whereas the piglets
received formula. The authors also concluded that the re-
sults indicated that HMA-piglets on a malnourished diet
displayed clinical symptoms mimicking the symptoms in
malnourished infants. Similarly, Fisher et al. [44], Kumar
et al. [89], Vlasova et al. [128], and Miyazaki et al. [129]
evaluated this pig model to be a valid tool to investigate
this research area. Microbiota composition of the donors
or recipients was not reported in these studies, though.
Further, the HMA-pig model has been used with vary-
ing purposes. Shen et al. [142] studied the impact of
short-chain fructo-oligosaccharides on the gut bacterial
populations; Che et al. [145] investigated the effects of
gut microbes from a different donor species on the in-
testinal morphology and mucosal immunity by compar-
ing HMA-pigs with pig microbiota associated pigs.
Discussion of the results
The described studies of Xiao et al. [45] and Brunse et
al. [46] showed the potential of using FMT to investigate
the pathology of human diseases or as a mean of treat-
ing them. The studies revealed that factors including
route of administration and donor have a marked impact
on the evolution of the diseases investigated, and indi-
cate that this pig model can help establishing the appro-
priate conditions to be applied for a successful FMT
treatment before being tested in humans. Although by
far proven, it could be speculated that a key factor relat-
ing to route of administration may be the compartment
of the gut that is most affected by disease. With admin-
istration of FMT directly to the site of insult (for ex-
ample the large intestine) being as important as the
transplant material. However, it is also evident from the
results that much knowledge is to be acquired before
FMT can be used to prevent or treat these diseases.
Regarding the HMA-pig model, maximum engraft-
ment would be considered the best outcome. The pres-
ence of bifidobacterium in HMA-pigs is considered by
several authors as an important parameter when evaluat-
ing this model as superior to rodents to investigate as-
pects with relevance to the human microbiome [38, 137,
145]. This genus is considered an important member of
the human gut, especially of breast-fed infants, and
while some studies have shown that bifidobacteria do
not readily colonize the rodent gut [146], other trials
have shown establishment of bifidobacteria in mice
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[147]. However, a more detailed taxonomic analysis of
the donor and recipient microbiota would be needed to
conclude on the level of engraftment in the various ani-
mal species. In our opinion, this aspect has not been
covered sufficiently, that is, comparison between the
donor and recipient microbiota comunnity is often not
statistically compared, which makes evaluation of the
model difficult.
At the same time, it should be pointed out that, as
previously discussed, the functional profile more than
the microbiota profile is relevant for the impact on the
host. Therefore, the arguments presented above suggest-
ing that the changes in phenotype in the recipients are
not caused by the compositional characteristics of the
engrafted microbiome, but by the ‘engrafted functions
[117], would be applicable here too.
All the studies described above using the HMA-pigs
model presented worked with germ-free piglets at birth/
delivered with cesarean-section and kept in isolators.
These conditions make this type of study cumbersome
and expensive. If pigs could be kept in non-sterilized
conditions, the use of this model would most probably
be more extended (cheaper, less specialized facilities
needed, etc.), and longer-term studies would also be
more affordable. This would require that the human
microbiota established would remain even when the en-
vironment is not sterile. Diet is a crucial factor that im-
pacts gut microbiota composition of pigs [16, 30, 148,
149]. Therefore, one possible model to try to maintain the
transplanted microbiota for a longer time even in a
non-sterilized environment (but also in germ-free models)
could be by feeding the HMA-pigs a human-like diet dur-
ing the study. To our knowledge, this has only been done
in studies using the piglet as a model for infants, in which
piglets were fed infant formula [46].
The importance of diet in the recipient animals in order
to maintain the established transplanted microbiota is also
discussed by Arrieta et al. [117] regarding mice, but there is
no reason to think that this would not hold for pigs, too.
Arrieta et al. [117] stated that it is likely that non-adapted
bacterial strains are unable to utilize host-specific growth
substrates (ie., glycans), and that reduced microbial adher-
ence to the mucosal surface may lead to the loss of
non-host adapted microbial species. Therefore, it is likely
that a human microbiome that colonizes a mouse is more
reliant on dietary growth substrates, as it has both limited
ability to utilize host-derived growth substrates and limited
interactions with surfaces that might support persistence
even if growth rates are reduced.
Conclusions and perspectives
With respect to the use of FMT in pigs when using this
animal as a model for humans, Kirk [150], in a review
on the use of larger animals and models in the context
of organ transplantation, stated that animal models can-
not be assumed to predict all aspects of subsequent hu-
man studies, but they can give data to meld with prior
human experience. This encourages to continue pursu-
ing improvement and development of pig (and other an-
imals) as a model for humans. Data indicate though, that
the pig has more similarities with the human regarding
the GI-tract ecosystem than other non-primate species,
what advocates for the inclusion of pig models at some
stage during the process of investigating aspects related
to humans within this area.
The use of FMT as a strategy to improve health, pre-
vent or treat disease, or feed efficiency in pigs is in its in-
fancy. The data available is scarce and does not allow
strong conclusions to be drawn on the effectiveness of
this strategy. The studies conducted so far have not re-
ported consistent results, that is, some have shown im-
provements in the phenotype of the recipients whereas
others have reported a negative impact.
There is a high number of factors that may be crucial
in order to obtain a successful outcome but have not
been identified yet. Examples of these are: donor selec-
tion and screening, e.g., microbiota profile, presence of
pathogenic microorganisms, age of donor with respect
to recipient; time of transplantation, e.g., at birth, at
weaning; frequency of transplantation; amount of trans-
plant; factors affecting engraftment extent, e.g., as for
organ transplantation, a match between donor and re-
cipient might be important; and preparation of the
transplant, e.g., only the pellet following centrifugation
of the faecal material or the whole material, procedure
to maximize viability. Another aspect is whether faecal/
colon material is the most appropriate material to be
transplanted regardless of the aim of the study, e.g., if
the purpose is to improve health related to processes oc-
curring in the small intestine, it would be prudent to as-
sess whether transplanting small intestinal digesta might
be more appropriate than faeces. An outline of import-
ant factors to be considered when practicing FMT are il-
lustrated in Fig. 1.
Faecal microbiota transplantation is a strategy that re-
sults in resolution rates of around 90% for rCDI in
humans, and, as such, it is worth investigating and de-
veloping FMT further in pig production both for pro-
duction improvement and disease treatment aspects. On
the other hand, it seems also clear that transplanting fae-
cal material from an individual to another poses a risk of
transmitting diseases or impairing other outcomes. Al-
though not examined in this review, and acting as some-
thing of a caveat for FMT in large-scale intensive pig
production, is the issue of biosecurity. As mentioned
above, and identified for human medicine, screening of
donor stock for pathogens is imperative. Multiple bac-
terial, parasitic, and viral agents can be transmitted via
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the faecal-oral route, and stock which have been treated
with antimicrobials may harbor resistant bacteria which
can be transferred to recipients, resulting in establish-
ment of the resistant population, or transfer of resistance
genes to the recipient’s commensal microbiota [151].
Additionally, it is common biosecurity practice to only
allow stock onto a production unit via an integrated sys-
tem, so a ‘one size fits all’ approach, where a large, easily
accessible stock of FMT inoculum can be distributed to
multiple producers is unlikely to be viable. It should be
noted that the use of FMT in pigs would also be sub-
jected to varying levels of regulations (based on country)
for its use in pigs due to biosecurity/regulatory implica-
tions [152]. The regulatory barriers for the routine use
of FMT in pigs require careful consideration and com-
prehensive risk-benefit assessment is also required to
any prior routine use.
When more experience has been gained on FMT in pigs
and taking advantage of this new knowledge, the future of
the field, as proposed for humans, should be moving be-
yond faecal transplants and instead aiming to identify the
organisms that are essential for a particular outcome, and
then providing those organisms in a much simpler fashion
than FMT. This would provide a safer and more sustain-
able alternative to faecal transplants. Probiotic products
are in common use in human therapeutics, and to a lesser
extent in animals, to alter GI-tract microbiota by provid-
ing specific microorganisms, however for the most part,
they do not seem to colonize and persist in the gut [153–
155]. Faecal microbiota transplantation consists of supple-
menting with an already established and competitive com-
munity, where much research will be needed to find
specific strains that will work synergistically to provide the
desired outcome, and be competitive enough to establish
in the host.
According to Smillie et al. [120], whether this next
generation of microbiome-based therapeutics effectively
replaces FMT will depend on i) whether the “active in-
gredients” of FMT that carry out a desired mechanism
can be identified, ii) whether these strains engraft in a
patient’s gut, and iii) whether they are sufficiently abun-
dant to produce a desired response. It could also be
added, particularly in a field of large scale as intensive
swine production, that a cost-effective, reproducible,
quality controlled product would also be needed.
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